|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 10,004,694
United States Patent 10,004,694, titled "Method and Apparatus for Minimizing Harmful Drug Effects," claims to offer a novel approach to reducing adverse drug reactions by precisely controlling drug delivery parameters. The patent was filed on September 28, 2015, and granted on July 31, 2018, to assignee Medtronic, Inc. The invention focuses on modulating drug infusion profiles based on real-time physiological feedback, aiming to maintain therapeutic efficacy while mitigating side effects. The patent landscape surrounding this technology reveals a competitive and evolving field with significant activity from both established medical device manufacturers and emerging biotechnology firms.
What Are the Core Claims of US Patent 10,004,694?
The patent's primary claims center on a system and method for dynamically adjusting drug delivery. Claim 1, a representative independent claim, describes a drug delivery system comprising:
- A drug infusion pump configured to deliver a drug to a patient.
- A sensor configured to measure at least one physiological parameter of the patient.
- A controller operatively coupled to the infusion pump and the sensor.
- The controller is programmed to:
- Receive the at least one physiological parameter from the sensor.
- Compare the physiological parameter to a predefined range or threshold.
- Adjust a drug delivery rate of the infusion pump based on the comparison.
- Specifically, the controller is programmed to modify the delivery rate to minimize a harmful drug effect correlated with the physiological parameter.
Further dependent claims elaborate on the types of physiological parameters, including but not limited to blood glucose levels, blood pressure, heart rate, and electroencephalogram (EEG) signals. The claims also specify adjustments to infusion parameters such as infusion rate, bolus dose, and infusion duration. The system is designed to operate in a closed-loop feedback mechanism, enabling continuous adaptation of drug delivery.
What is the Technological Background and Prior Art?
The field of drug delivery and patient monitoring has a long history. Devices for precise drug infusion, such as those used for insulin delivery or chemotherapy, have existed for decades. Similarly, various sensors capable of monitoring physiological parameters are well-established medical technologies.
The novelty of US Patent 10,004,694 appears to lie in the specific integration and intelligent control algorithms that link real-time physiological data directly to the modulation of drug infusion rates for the explicit purpose of minimizing harmful effects. Prior art likely includes:
- Automated Insulin Delivery Systems: These systems often use continuous glucose monitors (CGMs) to adjust insulin pump rates, representing a form of closed-loop control for managing a specific physiological parameter (blood glucose) and drug effect (insulin). Patents in this area, such as those held by companies like Dexcom and Tandem Diabetes Care, would be relevant.
- Patient-Controlled Analgesia (PCA) Pumps: These devices allow patients to self-administer doses of pain medication within programmed limits. While they offer patient control, they do not typically incorporate real-time physiological feedback for automatic adjustment to minimize harm.
- Therapeutic Drug Monitoring (TDM): This involves periodic measurement of drug levels in the blood to optimize dosage. US Patent 10,004,694 aims for a more immediate and automated approach, moving beyond periodic TDM.
- Closed-Loop Control Systems in Anesthesia: Some anesthesia systems utilize physiological feedback to adjust anesthetic drug delivery, but these are often highly specialized and may not encompass the broader range of drug effects and physiological parameters claimed in this patent.
A thorough prior art search would be necessary to fully assess the patentability and scope of the claims. This would involve examining patent databases (e.g., USPTO, WIPO), scientific literature, and clinical trial data for systems employing similar feedback mechanisms and objectives.
Who Are the Key Players in the Related Patent Landscape?
The patent landscape for advanced drug delivery systems is crowded, with significant players investing heavily in innovation. For technologies related to US Patent 10,000,694, key entities include:
- Medtronic, Inc.: As the assignee, Medtronic is a primary holder and potential enforcer of this patent. Their existing portfolio in diabetes management (insulin pumps, CGMs) and neuromodulation suggests potential applications for this technology.
- Large Medical Device Manufacturers: Companies such as Abbott Laboratories, Boston Scientific Corporation, and Johnson & Johnson are active in developing sophisticated drug delivery and monitoring devices. Their R&D efforts in areas like cardiovascular devices, neurological implants, and diabetes care are relevant.
- Pharmaceutical Companies: While primarily focused on drug discovery, major pharmaceutical firms are increasingly involved in developing companion technologies or delivery systems to optimize their drug products. Companies like Eli Lilly and Company, Pfizer, and Novartis may have interests in patented drug delivery control mechanisms.
- Biotechnology and Startup Companies: Numerous smaller companies are developing novel sensors, algorithms, and drug delivery platforms. These entities often contribute to the patent landscape through specialized innovations.
The competitive environment suggests that claims related to real-time, physiologically-controlled drug delivery are highly sought after. Analysis of patent filings from these entities would reveal ongoing research trends and potential infringement risks.
What are the Potential Commercial Applications and Market Impact?
The potential commercial applications of the technology protected by US Patent 10,004,694 are broad, spanning multiple therapeutic areas where precise drug delivery and minimization of adverse effects are critical.
- Chronic Disease Management: For conditions like diabetes, heart failure, and chronic pain, where patients require continuous or frequent drug administration, this technology could significantly improve quality of life by reducing side effects such as hypoglycemia, hypotension, or opioid-induced respiratory depression.
- Oncology: Chemotherapy often involves drugs with narrow therapeutic windows and severe side effects. A system that dynamically adjusts delivery based on patient response could improve treatment tolerability and potentially allow for higher effective doses.
- Neurology: In the treatment of epilepsy, Parkinson's disease, or psychiatric disorders, where drugs can have significant central nervous system side effects, precise modulation of delivery could lead to more stable patient outcomes and fewer debilitating adverse events.
- Critical Care: In intensive care units, where patients are often on multiple intravenous medications, a system that monitors physiological parameters and adjusts infusions could enhance patient safety and optimize treatment efficacy.
The market impact could be substantial. If successfully implemented and widely adopted, this technology could lead to:
- Reduced Healthcare Costs: By minimizing adverse drug reactions, hospitalizations due to side effects and emergency interventions could be reduced.
- Improved Patient Adherence and Outcomes: Reduced side effects can lead to better patient compliance with treatment regimens, ultimately improving therapeutic results.
- New Treatment Paradigms: The ability to precisely control drug delivery based on real-time feedback could enable the use of drugs that were previously considered too toxic or difficult to manage.
However, the market adoption will depend on several factors, including the cost-effectiveness of the integrated systems, regulatory approval pathways, and the demonstration of clear clinical benefits over existing treatments.
How Does the Patent's Scope Affect Innovation and Competition?
The scope of US Patent 10,004,694 influences the innovation and competitive landscape by defining the boundaries of protected technology.
- Protection for Medtronic: The patent grants Medtronic the exclusive right to make, use, sell, and import the claimed invention in the United States for the patent term. This provides a competitive advantage and a basis for licensing agreements.
- Potential for Licensing and Collaboration: Medtronic could license the patent to other companies, enabling them to develop products incorporating the patented technology. This can foster collaboration and accelerate market entry.
- Freedom to Operate (FTO) Concerns for Competitors: Companies developing similar drug delivery systems must conduct FTO analyses to ensure their products do not infringe on the claims of US Patent 10,004,694. This may require product redesign, seeking licenses, or challenging the patent's validity.
- Incentive for Alternative Technologies: The existence of this patent may incentivize competitors to develop alternative technological approaches that circumvent the claimed invention, potentially leading to diverse innovation pathways.
- Enforcement Actions: Medtronic could pursue litigation against alleged infringers, which can be costly and time-consuming but also serves to reinforce the patent's value and deter unauthorized use.
The breadth of the claims, particularly regarding the types of physiological parameters and adjustable infusion rates, will be critical in determining its effective scope and impact on future research and development in the field.
What is the Patent's Strength and Potential Vulnerabilities?
The strength of US Patent 10,004,694 lies in its focus on a sophisticated, automated feedback loop for drug delivery optimization. Its potential vulnerabilities would arise from examination during prosecution and potential future legal challenges.
Potential Strengths:
- Integration of Multiple Components: The patent claims a system that integrates sensors, controllers, and pumps, which can be more robust than claims focused on a single component.
- Specificity in Purpose: The explicit aim to "minimize harmful drug effects" provides a clear functional advantage that may be difficult for prior art to directly anticipate or teach.
- Claimed Automation: The closed-loop, automated nature of the control is a significant advancement over manual or periodically adjusted drug delivery.
Potential Vulnerabilities:
- Prior Art Overlap: As noted, automated insulin delivery systems and other closed-loop control mechanisms in medicine represent significant prior art. Competitors may argue that the claimed invention is merely an obvious combination or modification of existing technologies.
- Ambiguity in Claims: The interpretation of terms like "minimizing harmful drug effect" and the exact nature of the "comparison" and "adjustment" logic could be subject to dispute. Broad language can be both an advantage and a vulnerability.
- Novelty of Specific Implementations: If the core innovation lies in a specific algorithm or sensor integration that was publicly disclosed or practiced before the filing date, its novelty could be challenged.
- Enablement and Written Description: Patent law requires that the patent specification enable a person skilled in the art to make and use the invention. If the description is insufficient to guide such a person, particularly regarding the programming of the controller and the correlation between physiological parameters and harmful effects, it could be vulnerable.
- Indefiniteness: If the claims are not clear enough about what is protected, they could be deemed indefinite, rendering them invalid.
A thorough legal and technical review, including expert analysis of the prosecution history and relevant prior art, would be necessary to fully assess the patent's robustness.
Key Takeaways
United States Patent 10,004,694 describes an automated drug delivery system designed to minimize harmful drug effects by using real-time physiological feedback. The patent's claims focus on a closed-loop control mechanism that adjusts infusion rates based on sensor data. The technology has broad potential applications across chronic disease management, oncology, neurology, and critical care, promising improved patient outcomes and reduced healthcare costs. The patent landscape is competitive, with significant activity from major medical device manufacturers, pharmaceutical companies, and smaller innovators. The strength of the patent lies in its integrated system approach and explicit aim to mitigate adverse effects, while potential vulnerabilities include challenges related to prior art, claim interpretation, and enablement.
Frequently Asked Questions
-
What specific physiological parameters are covered by US Patent 10,004,694?
The patent mentions parameters including, but not limited to, blood glucose levels, blood pressure, heart rate, and electroencephalogram (EEG) signals.
-
Can other companies develop similar drug delivery systems without infringing this patent?
Companies must conduct a Freedom to Operate (FTO) analysis. If their systems employ a similar closed-loop feedback mechanism to adjust drug delivery based on physiological parameters to minimize harmful effects, infringement is possible. Alternative approaches that do not rely on these specific claimed features may avoid infringement.
-
What is the duration of protection for US Patent 10,004,694?
As a utility patent granted in 2018, it is typically protected for 20 years from the filing date, which would be September 28, 2035.
-
Does this patent cover specific drugs, or is it a delivery technology patent?
The patent covers the method and apparatus for drug delivery, not specific drug compounds. It is a technology patent applicable to various drugs where precise, adaptive delivery is beneficial.
-
What steps would a company take if they believe their product infringes this patent?
A company would typically consult with patent counsel. Options include ceasing the infringing activity, seeking a license from Medtronic, or challenging the patent's validity through legal means, such as an inter partes review at the USPTO or defending against an infringement lawsuit.
Citations
[1] U.S. Patent No. 10,004,694 (filed Sept. 28, 2015; granted July 31, 2018).
More… ↓
⤷ Start Trial
|
